{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:11:11Z","timestamp":1771935071912,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Screening for spinal muscular atrophy (SMA) was adopted by all US state newborn screening programs between 2018 and 2024; by the end of 2022, 48 states were screening for SMA. We assessed trends in health insurance records of SMA diagnoses to quantify improvements in the timeliness of SMA identification following the adoption of screening. We used nationally representative Medicaid claims data for approximately half of US births covered by public insurance and a convenience sample of employer-sponsored health plans. We analyzed records for birth cohorts with at least 1 full year of follow-up (i.e., through the end of the following calendar year). For 2017 births, 1.3 per 100,000 infants had SMA codes first recorded by 1 month of age; this increased to 6.6 per 100,000 among publicly insured newborns born in 2022. The rollout of SMA newborn screening across US states was also followed by improvements in the timely detection of SMA. The proportion of infants with SMA detected by 1 month increased from 18% in 2017 to 61% in 2021 and is projected to reach 75% in 2022. Growth in timely detection was even greater in the employer-insured sample. Timely diagnosis of SMA can enable the initiation of treatment prior to the irreversible loss of motor function.<\/jats:p>","DOI":"10.3390\/ijns12010009","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:28:18Z","timestamp":1771428498000},"page":"9","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in the Timeliness of Spinal Muscular Atrophy Detection in US Infants, 2016\u20132023"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1078-6855","authenticated-orcid":false,"given":"Scott D.","family":"Grosse","sequence":"first","affiliation":[{"name":"Division of Laboratory Sciences, Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA"},{"name":"Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55545, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-4491","authenticated-orcid":false,"given":"Kai","family":"Hong","sequence":"additional","affiliation":[{"name":"Office of Policy, Performance, and Evaluation, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golriz K.","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Division of Laboratory Sciences, Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Nash","sequence":"additional","affiliation":[{"name":"Division of Laboratory Sciences, Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Gaviglio","sequence":"additional","affiliation":[{"name":"Division of Laboratory Sciences, Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA"},{"name":"Association of Public Health Laboratories, Silver Spring, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Division of Laboratory Sciences, Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra A. K.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53792, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref_1","unstructured":"National Academies of Science, Engineering, and Medicine (2025). Newborn Screening in the United States: A Vision for Sustaining and Advancing Excellence, National Academies Press."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2011). Ten great public health achievements\u2014United States, 2001\u20132010. MMWR Morb. Mortal. Wkly. Rep., 60, 619\u2013623."},{"key":"ref_3","unstructured":"US Department of Health and Human Services (2025, November 18). Newborn Screening Timeliness Goals, Available online: https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/newborn-screening-timeliness#:~:text=Initial%20NBS%20specimens%20should%20be,September%202017."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jones, E., Singh, S., McKasson, S., Sheller, R., Ojodu, J., and Comer, A. (2025). Learning Collaborative to Support Continuous Quality Improvement in Newborn Screening. Int. J. Neonatal Screen., 11.","DOI":"10.3390\/ijns11030070"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ppul.10110","article-title":"Spinal muscular atrophy type 1: Management and outcomes","volume":"34","author":"Bach","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y., and Awano, H. (2023). Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511939"},{"key":"ref_8","unstructured":"Kemper, A.R., Lam, K., Comeau, A.M., Kwon, J., Green, N.S., Ojodu, J., Grosse, S., Prosser, L.A., Jones, E., and Tanksley, S. (2018). Evidence-Based Review of Newborn Screning for Spinal Muscular Atrophy (SMA): Final Report (v5.2), Maternal and Child Health Bureau, Department of Health and Human Services."},{"key":"ref_9","first-page":"1300","article-title":"The Effectiveness and Value of Treatments for Spinal Muscular Atrophy","volume":"25","author":"Pearson","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy via Newborn Screening Who Have 4 Copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lee, F.K., Greene, C., Mercer, K., Taylor, J., Yazdanpanah, G., Vogt, R., Lee, R., Cuthbert, C., and Cordovado, S. (2024). CDC\u2019s Laboratory Activities to Support Newborn Screening for Spinal Muscular Atrophy. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030051"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kellar-Guenther, Y., McKasson, S., Hale, K., Singh, S., Sontag, M.K., and Ojodu, J. (2020). Implementing Statewide Newborn Screening for New Disorders: U.S. Program Experiences. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6020035"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Singh, S., Ojodu, J., Kemper, A.R., Lam, W.K.K., and Grosse, S.D. (2023). Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010\u20132018. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9020020"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Shih, S.T.F., Keller, E., Wiley, V., Farrar, M.A., Wong, M., and Chambers, G.M. (2022). Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency. Int. J. Neonatal Screen., 8.","DOI":"10.3390\/ijns8030045"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wong, K.N., McIntyre, M., Cook, S., Hart, K., Wilson, A., Moldt, S., Rohrwasser, A., and Butterfield, R.J. (2024). A Five-Year Review of Newborn Screening for Spinal Muscular Atrophy in the State of Utah: Lessons Learned. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030054"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gaviglio, A., McKasson, S., Singh, S., and Ojodu, J. (2023). Infants with Congenital Diseases Identified through Newborn Screening-United States, 2018\u20132020. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9020023"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1177\/22143602241288095","article-title":"Newborn screening programs for spinal muscular atrophy worldwide in 2023","volume":"11","author":"Vrscaj","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cooper, K., Nalbant, G., Sutton, A., Harnan, S., Thokala, P., Chilcott, J., McNeill, A., and Bessey, A. (2024). Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030049"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","article-title":"Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US","volume":"178","author":"Belter","year":"2024","journal-title":"JAMA Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zaidman, C.M., Crockett, C.D., Wedge, E., Tabatabai, G., and Goedeker, N. (2024). Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030058"},{"key":"ref_22","unstructured":"National Academies of Science, Engineering, and Medicine (2020). Birth Settings in America: Outcomes, Quality, Access, and Choice, National Academies Press."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1007\/s10803-021-05269-1","article-title":"Heterogeneity in Autism Spectrum Disorder Case-Finding Algorithms in United States Health Administrative Database Analyses","volume":"52","author":"Grosse","year":"2022","journal-title":"J. Autism Dev. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","article-title":"Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis","volume":"40","author":"Fox","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13023-023-02872-6","article-title":"Prevalence of morbidities across the lifespan for adults with spinal muscular atrophy: A retrospective cohort study","volume":"18","author":"Whitney","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1843277","DOI":"10.1080\/20016689.2020.1843277","article-title":"Economic burden of spinal muscular atrophy: An analysis of claims data","volume":"8","author":"Belter","year":"2020","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JND-210764","article-title":"Disease Burden of Spinal Muscular Atrophy: A Comparative Cohort Study Using Insurance Claims Data in the USA","volume":"10","author":"Mouchet","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","article-title":"The economic burden of spinal muscular atrophy","volume":"19","author":"Armstrong","year":"2016","journal-title":"J. Med. Econ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13696998.2021.2013676","article-title":"Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada","volume":"24","author":"Chen","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_30","unstructured":"(2025, November 13). Number of births in the United States from 1990 to 2023. Available online: https:\/\/www.statista.com\/statistics\/195908\/number-of-births-in-the-united-states-since-1990\/?srsltid=AfmBOorb6KyFB2IlTzpAFtX1ZKn1YN0gfYC7khsvikdM1UQYP3nb-Utd."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"Bertini","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","article-title":"Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial","volume":"178","author":"Schwartz","year":"2024","journal-title":"JAMA Pediatr."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Masson, R., Gaballo, S., Caravita, R., and Parravicini, S. (2025). Treating Presymptomatic Spinal Muscular Atrophy Patients with Onasemnogene Abeparvovec in Italy: The Role of the National Health System and Drug Supply. Comment on Zaidman et al. Newborn Screening for Spinal Muscular Atrophy: Variations in Practice and Early Management of Infants with Spinal Muscular Atrophy in the United States. Int. J. Neonatal Screen. 2024, 10, 58. Int. J. Neonatal Screen., 11.","DOI":"10.3390\/ijns11040102"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70016","DOI":"10.1002\/pmf2.70016","article-title":"An overview of current prenatal genetic screening and diagnosis guidelines","volume":"1","author":"Santoli","year":"2025","journal-title":"Pregnancy"}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/12\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:08:39Z","timestamp":1771931319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/12\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijns12010009"],"URL":"https:\/\/doi.org\/10.3390\/ijns12010009","relation":{},"ISSN":["2409-515X"],"issn-type":[{"value":"2409-515X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}